Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.57 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025496 | 0.82 | ALDH1A1 (0.55) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL340086 | 0.78 | NPC1 (0.60) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL28158455 | 0.78 | CA1 (0.50) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL29950410 | 0.78 | ALDH1A1 (0.61) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL67498 | 0.78 | ALDH1A1 (0.61) | TRIM24TYRTRIM33NPC1RAB9A | |
| Formaldehyde SCHEMBL8164524 | 0.77 | NPC1 (0.59) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL16475652 | 0.77 | TRIM24 (0.67) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL929945 | 0.74 | CYP3A4 (0.56) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL7672389 | 0.74 | CA1 (0.46) | TRIM24TYRTRIM33NPC1RAB9A | |
| SCHEMBL581508 | 0.74 | TUBB4A (0.63) | TRIM24TYRTRIM33NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178959-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-05-17 | — | — | EP | claimed |
| WO-2023078482-A1 | HETEROCYCLIC PURINE CYTOKININ DERIVATIVES, THEIR USE IN WOUND HEALING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2023-05-11 | — | — | WO | claimed |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | claimed |
| US-11566058-B2 | Process for the preparation of high purity glucagon | Fresenius Kabl iPSUM S.R.L. (IT) | 2023-01-31 | — | — | US | claimed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | claimed |
| WO-2022012702-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2022-01-20 | — | — | WO | claimed |
| US-20200399339-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY GLUCAGON | Fresenius Kabi Ipsum S.R.L. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3753946-A1 | IMPROVED PROCESS FOR THE PREPARATION OF HIGH PURITY GLUCAGON | Fresenius Kabi iPSUM S.r.l. (IT) | 2020-12-23 | — | — | EP | claimed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | claimed |
| EP-3615535-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2020-03-04 | — | — | EP | claimed |
| CN-1351587-A | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2002-05-29 | — | — | CN | claimed |
| EP-1204679-A1 | PEPTIDES CONTAINING N-SUBSTITUTED D-AMINO ACIDS FOR PREVENTING BETA-STRAND ASSOCIATION | Stott, Kelvin (GB) | 2002-05-15 | — | — | EP | claimed |
| EP-1203019-A1 | PEPTIDES CONTAINING N-SUBSTITUTED L-AMINO ACIDS FOR PREVENTING BETA-STRAND ASSOCIATION | Stott, Kelvin (GB) | 2002-05-08 | — | — | EP | claimed |
| EP-1173413-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | Novartis AG (CH) | 2002-01-23 | — | — | EP | claimed |
| EP-1115738-A1 | SYNTHESIS OF CYCLIC PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-07-18 | — | — | EP | claimed |
| WO-2001007473-A1 | PEPTIDES CONTAINING N-SUBSTITUTED L-AMINO ACIDS FOR PREVENTING BETA-STRAND ASSOCIATION | STOTT KELVIN (GB) | 2001-02-01 | — | — | WO | claimed |
| WO-2001007474-A1 | PEPTIDES CONTAINING N-SUBSTITUTED D-AMINO ACIDS FOR PREVENTING BETA-STRAND ASSOCIATION | STOTT KELVIN (GB) | 2001-02-01 | — | — | WO | claimed |
| WO-2000064863-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2000-11-02 | — | — | WO | claimed |
| WO-2000018790-A1 | SYNTHESIS OF CYCLIC PEPTIDES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-04-06 | — | — | WO | claimed |
| EP-0615969-A1 | 2,4-Diamino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD. (CH) | 1994-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566058-B2 | Process for the preparation of high purity glucagon | IAPP, GCG, GLP1R | TRIM24 1703/4885TYR 193/4885TRIM33 3340/4885 |
| US-20200399339-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY GLUCAGON | IAPP, GCG, GLP1R | TRIM24 1703/4885TYR 193/4885TRIM33 3340/4885 |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | ADORA2A, UNG, P2RY6 | TRIM24 4268/4885TYR 47/4885TRIM33 4359/4885 |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | ADORA2A, UNG, P2RY6 | TRIM24 4268/4885TYR 47/4885TRIM33 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.